Consolidation Therapy with Checkpoint Inhibitors After Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Multiple Myeloma and Lymphoma
- 15 May 2026
- journal article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (9) , 1078.e1-1078.e4
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage ChemotherapyTransplantation and Cellular Therapy, 2024
- Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myelomaAmerican Journal of Hematology, 2021
- Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell TransplantationTransplantation and Cellular Therapy, 2021
- Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer TreatmentJournal of Clinical Oncology, 2008
- Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathwayBlood, 2007